Medicare expands dialysis coverage, but pricing guardrails unclear

What it does

This bill expands Medicare coverage to include treatments for dialysis-related amyloidosis (a protein-buildup disease affecting dialysis patients) that are FDA-approved. It requires Medicare to pay 100% of reasonable charges for these treatments when delivered in dialysis facilities, separate from the standard dialysis payment system. The bill takes effect immediately upon enactment.

Why we flagged it

The bill's operative mechanism is straightforward: it adds a new covered service category to Medicare and mandates separate payment at 100% of reasonable charges. This is a standard coverage-and-payment amendment, not a carve-out or immunity grant.

What the text implies

• 100% payment at 'reasonable charges' (not a capped prospective rate) may create pricing pressure if 'reasonable' is not tightly defined by CMS; dialysis providers may have incentive to bill aggressively for DRA treatments.
• Exclusion from renal dialysis prospective payment system means DRA treatments bypass the bundled payment model, potentially fragmenting care coordination and creating separate billing streams.
• Bill does not specify which FDA-approved DRA treatments qualify or establish a formulary; coverage scope depends entirely on FDA approval status at time of service, creating potential coverage uncertainty.
• No mention of prior authorization, medical necessity review, or utilization controls; open-ended coverage at 100% of reasonable charges may drive higher utilization and Medicare spending growth.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries with dialysis-related amyloidosis gain access to FDA-approved treatments previously not covered, with full payment by Medicare (no cost-sharing). Dialysis patients facing this complication now have a clear pathway to treatment without out-of-pocket expense or coverage denial.

Who stands to gain

• dialysis facility operators (freestanding and hospital-based)
• manufacturers of FDA-approved DRA treatments
• dialysis service providers

Named in the bill

Medicare, Social Security Act, Food and Drug Administration (FDA), dialysis facilities, Centers for Medicare & Medicaid Services (CMS)

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Jun 20, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 20, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.